<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">There are also developments of oncolytic influenza A viruses, which are based on attenuation markers other than the NS1 deletion. One preclinical study in murine non-small cell lung cancer (NSCLC) xenografts showed efficacy and safety of wild-type NS1, laboratory adapted, PR8 H1N1 virus
 <sup>
  <xref ref-type="bibr" rid="CR66">66</xref>
 </sup>. Another study screened a variety of wild-type influenza A viruses for their infectivity in pancreatic carcinoma cell lines and showed oncolytic effectiveness in a mouse model of human pancreatic cancer
 <sup>
  <xref ref-type="bibr" rid="CR67">67</xref>
 </sup>. Similarly, the seasonal flu vaccination has recently been assessed for sensitizing murine B16 melanoma models to immune check point inhibitor therapy, which showed promising results
 <sup>
  <xref ref-type="bibr" rid="CR24">24</xref>
 </sup>.
</p>
